GeneDx Holdings Corp. Reports Director Departure, Officer Changes
Ticker: WGSWW · Form: 8-K · Filed: Sep 18, 2025 · CIK: 1818331
| Field | Detail |
|---|---|
| Company | Genedx Holdings Corp. (WGSWW) |
| Form Type | 8-K |
| Filed Date | Sep 18, 2025 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.0001, $379.50, $420,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: director-departure, officer-appointment, corporate-governance, financials
TL;DR
GeneDx board shakeup: Director out, new officers in, plus financials filed.
AI Summary
GeneDx Holdings Corp. announced on September 17, 2025, the departure of Director Dr. Jonathan S. Roth. The company also reported on the election of new directors and the appointment of certain officers, along with details on compensatory arrangements for these officers. The filing also includes financial statements and exhibits.
Why It Matters
Changes in board composition and officer appointments can signal shifts in company strategy or governance, potentially impacting future performance.
Risk Assessment
Risk Level: medium — Director departures and executive appointments can indicate internal changes that may affect business operations and strategy.
Key Players & Entities
- GeneDx Holdings Corp. (company) — Registrant
- Dr. Jonathan S. Roth (person) — Departing Director
- September 17, 2025 (date) — Date of Report
- Delaware (jurisdiction) — State of Incorporation
- Sema4 Holdings Corp. (company) — Former Company Name
- CM Life Sciences, Inc. (company) — Former Company Name
FAQ
Who has departed from the board of GeneDx Holdings Corp.?
Dr. Jonathan S. Roth has departed from the board of GeneDx Holdings Corp.
What is the date of the earliest event reported in this 8-K filing?
The earliest event reported is dated September 17, 2025.
What are the main items reported in this 8-K filing?
The filing reports the departure of a director, election of directors, appointment of officers, compensatory arrangements, and financial statements and exhibits.
What was GeneDx Holdings Corp. formerly known as?
GeneDx Holdings Corp. was formerly known as Sema4 Holdings Corp. and CM Life Sciences, Inc.
In which state was GeneDx Holdings Corp. incorporated?
GeneDx Holdings Corp. was incorporated in Delaware.
Filing Stats: 845 words · 3 min read · ~3 pages · Grade level 11.5 · Accepted 2025-09-18 08:16:49
Key Financial Figures
- $0.0001 — stered Class A common stock, par value $0.0001 per share WGS The Nasdaq Stock Market L
- $379.50 — mon stock, each at an exercise price of $379.50 per share WGSWW The Nasdaq Stock Market
- $420,000 — al restricted stock unit grant equal to $420,000, which will vest over the three-year pe
Filing Documents
- wgs-20250917.htm (8-K) — 27KB
- wgs-20250917_g1.jpg (GRAPHIC) — 16KB
- 0001818331-25-000121.txt ( ) — 236KB
- wgs-20250917.xsd (EX-101.SCH) — 2KB
- wgs-20250917_def.xml (EX-101.DEF) — 17KB
- wgs-20250917_lab.xml (EX-101.LAB) — 29KB
- wgs-20250917_pre.xml (EX-101.PRE) — 17KB
- wgs-20250917_htm.xml (XML) — 4KB
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No Description 104 Cover Page Interactive Data File (the cover page XBRL tags are embedded within the inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. GENEDX HOLDINGS CORP. Date: September 18, 2025 By: /s/ Katherine Stueland Name: Katherine Stueland Title: Chief Executive Officer